Published in Hematology Week, October 15th, 2007
StemCyte's CEO Ken Giacin credits growing acceptance of umbilical cord blood stem cells for transplantation and StemCyte's outstanding record of favorable clinical outcomes for patients with leukemia and other blood diseases for the Company's excellent growth record.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.